Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 68

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists

Francis, Sharron H., Corbin, Jackie D.·2003·Current Urology Reports
DOI 10.1007/s11934-003-0027-x
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11934-003-0027-x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 48

  1. Robison GA, Butcher RW, Sutherland EW: Cyclic AMP. New York: Academic Press; 1971.
  2. Burns F, Zhao AZ, Beavo JA: Cyclic nucleotide phosphodiesterases: gene complexity, regulation by phosphorylation, and physiologic implications. Adv Pharmacol Academic Press 1996, 36:29–48. · DOI
  3. Corbin JD, Francis SH: Cyclic GMP phosphodiesterase-5: target for sildenafil. J Biol Chem 1999, 274:13729–13732. Presents the basic biochemistry and physiology of PDE-5 and PDE-5 inhibitors. · DOI
  4. Francis SH, Turko IV, Corbin JD: Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol 2001, 65:1–52. · DOI
  5. Soderling SH, Beavo JA: Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol 2000, 12:174–179. · DOI
  6. Jeremy JY, Ballard SA, Naylor AM, et al.: Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br J Urol 1997, 79:958–963. · DOI
  7. Ballard SA, Gingell CJ, Tang K, et al.: Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 1998, 159:2164–2171. · DOI · Paper page
  8. Rotella DP: Phosphodiesterase 5 inhibitors: current status and potential applications. Nat Rev Drug Discov 2002, 1:674–682. Reviews preclinical and clinical aspects of sildenafil, tadalafil, and vardenafil. · DOI · Paper page
  9. Hellstrom WJ, Gittelman M, Karlin G, et al.: Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002, 23:763–771. · DOI · Paper page
  10. Klotz T, Sachse R, Heidrich A, et al.: Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J Urol 2001, 19:32–39. · DOI
  11. Lue TF: Erectile dysfunction. N Engl J Med 2000, 324:1801–1813.
  12. Montorsi F, Salonia A, Deho F, et al.: Pharmacological management of erectile dysfunction. BJU Int 2003, 91:446–454. · DOI
  13. Padma-Nathan H, Rosen RC, Shobsigh R, et al.: Cialis (IC351) provides prompt response and extended responsiveness for the treatment of erectile dysfunction. J Urol 2001, 164(suppl):224.
  14. Padma-Nathan H, Porst H, Eardley I, Thibonnier M: Efficacy and safety of tadalafil in men with erectile dysfunction with and without hypertension. Am J Hypertens 2002, 15:143A. · DOI
  15. Hellstrom WJ, Gittelman M, Karlin G, et al.: Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology 2003, 61:8–14. · DOI
  16. Atz AM, Lefler AK, Fairbrother DL, et al.: Sildenafil augments the effects of inhaled nitric oxide for postoperative pulmonary hypertensive crises. J Thorac Cardiovasc Surg 2002, 124:628–629. · DOI
  17. Bortolotti M, Mari C, Lopilato C, et al.: Effects of sildenafil on esophageal motility of patients with idiopathic achalasia. Gastroenterology 2000, 118:253–257. · DOI
  18. Ghofrani HA, Wiedemann R, Rose F, et al.: Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomized controlled trial. Lancet 2002, 360:895–900. · DOI · Paper page
  19. Jackson G, Chambers J: Sildenafil for primary pulmonary hypertension: short- and long-term symptomatic benefit. Int J Clin Pract 2002, 56:397–398. · DOI
  20. Lichenstein JR: Use of sildenafil citrate in Raynaud’s phenomenon: comment on the article by Thompson et al. Arthritis Rheum (letter) 2003, 48:282–283. · DOI
  21. Nakamizo T, Kawamata J, Yoshida K, et al.: Phosphodiesterase inhibitors are neuroprotective to cultured spinal motor neurons. J Neurosci Res 2003, 71:485–495. · DOI
  22. Vardi Y, Klein L, Nassar S, et al.: Effects of sildenafil citrate (Viagra) on blood pressure in normotensive and hypertensive men. Urology 2002, 59:747–752. · DOI
  23. Sadovsky R, Miller T, Moskowitz M, Hackett G: Three-year update of sildenafil citrate (Viagra) efficacy and safety. Int J Clin Pract 2001, 55:115–128. · DOI
  24. Kloner RA, Brown M, Prisant LM, Collins M: Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study Group. Am J Hypertens 2001, 14:70–73. · DOI
  25. Herrmann HC, Chang G, Klugherz BD, Mahoney PD: Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000, 342:1622–2626. · DOI · Paper page
  26. Padma-Nathan H, Eardley I, Kloner RA, et al.: A 4-year update on the safety of sildenafil citrate (Viagra). Urology 2003, 60:67–90. · DOI
  27. Wallis RM, Corbin JD, Francis SH, Ellis P: Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of traveculae carneae and aortic rings in vitro. Am J Cardiol 1999, 83:3C-12C. · DOI
  28. Jackson G, Benjamin N, Jackson N, Allen MJ: Effects of sildenafil citrate on human hemodynamics. Am J Cardiol 1999, 83:13C-20C. · DOI · Paper page
  29. Gopal VG, Francis SH, Corbin JD: Allosteric sites of phosphodiesterase-5 (PDE-5): a potential role in negative feedback regulation of cGMP signaling in corpus cavernosum. Eur J Biochem 2001, 268:3304–3312. · DOI
  30. Francis SH, Corbin JD: Cyclic nucleotide-dependent protein kinases: intracellular receptors for cAMP and cGMP action. Crit Rev Clin Lab Sci 1999, 36:275–328. · DOI · Paper page
  31. Lincoln TM, Dey N, Sellak H: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression. J Appl Physiol 2001, 91:1421–1430. · DOI
  32. Schlossmann J, Feil R, Hofmann F: Signaling through NO and cGMP-dependent protein kinases. Ann Med 2003, 35:21–27. · DOI
  33. Ignarro LJ, Degnan JN, Baricos WH, et al.: Activation of purified guanylate cyclase by nitric oxide requires heme: comparison of heme-deficient, heme-reconstituted, and hemecontaining forms of soluble enzyme from bovine lung. Biochim Biophys Acta 1982, 718:49–59. · DOI
  34. Ignarro LJ, Bush PA, Buga GM, et al.: Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun 1990, 170:843–850. · DOI · Paper page
  35. McAllister-Lucas LM, Sonnenburg WK, Kadlecek A, et al.: The structure of a bovine lung cGMP-binding cGMP-specific phosphodiesterase deduced from a cDNA clone. J Biol Chem 1993, 268:22863–22873. · DOI
  36. Turko IV, Ballard SA, Francis SH, Corbin JD: Inhibition of cyclic GMP binding, cyclic GMP specific phosphodiesterase 5 by sildenafil, and related compounds. Mol Pharmacol 1999, 56:124–130. · DOI
  37. Francis SH, Thomas MK, Corbin JD: Cyclic GMP-binding cyclic GMP-specific phosphodiesterase from lung. In Cyclic Nucleotide Phosphodiesterases: Structure, Regulation, and Drug Action. Edited by Beavo J, Houslay M. New York: John Wiley & Sons; 1990:117–140.
  38. Corbin JD, Turko IV, Beasley A, Francis SH: Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. Eur J Biochem 2000, 267:2760–2767. Covers physiologic regulation of PDE-5 by phosphorylation. · DOI · Paper page
  39. Rybalkin SD, Rybalkina IG, Shimizu-Albergine M, et al.: PDE-5 is converted to an activated state upon cGMP binding to the GAF A domain. EMBO J 2003, 22:469–478. · DOI
  40. Mullershausen F, Friebe A, Feil R, et al.: Direct activation of PDE-5 by cGMP: long-term effects within NO/cGMP signaling. J Cell Biol 2003, 160:719–727. · DOI
  41. Corbin JD, Blount MA, Weeks JL 2nd, et al.: [3H]Sildenafil binding to phosphodiesterase-5 is specific, kinetically heterogeneous, and stimulated by cGMP. Mol Pharmacol 2003, 63:1364–1372. Demonstration of a new measurement of PDE-5 inhibitor potency using direct binding of radio-labeled inhibitor. Proof that PDE-5 inhibitors potentiate their own effects on penile erection. · DOI
  42. Loughney K, Hill TR, Florio VA, et al.: Isolation and characterization of cDNAs encoding PDE-5A, a human cGMP binding, cGMP specific 3′,5′-cyclic nucleotide phosphodiesterase. Gene 1998, 216:139–147. · DOI
  43. Lin CS, Lau A, Tu R, Lue TF: Expression of three isoforms of cGMP-binding, cGMP-specific phosphodiesterase (PDE-5) in human penile tissue. Biochem Biophys Res Commun 2000, 268:628–635. · DOI
  44. Hutter AM, Kloner RA, Watkins V, et al.: Blood pressure and cardiovascular effects of tadalafil, a new PDE-5 inhibitor. Am J Hypertens 2002, 15:140A. · DOI
  45. Porst H, Rosen R, Padma-Nathan H, et al.: The efficacy and tolerability of vardenafil, a new oral selective phosphodiesterase type 5 inhibitor in patients with erectile dysfunction: the first at-home clinical trial. Int J Impotence Res 2001, 13:192–199. · DOI
  46. Berkels R, Klotz T, Sticht G, et al.: Modulation of human platelet aggregation by the phosphodiesterase type 5 inhibitor sildenafil. J Cardiovasc Pharmacol 2001, 37:413–421. · DOI
  47. Corbin J, Rannels S, Neal D, et al.: Sildenafil citrate does not affect cardiac contractility in human or dog heart. Curr Med Res Opin 2003, 19:747–752. · DOI
  48. Porst H, Rosen RC, Padma-Nathan H, et al.: Tadalafil allows men with erectile dysfunction to have successful intercourse up to 36 hours postdose. J Urol, 2002 167(suppl):177.

Cited by

Metadata

Authors
Francis, S. H., & Corbin, J. D.
Venue
Current Urology Reports
Publisher
Springer Science and Business Media LLC
Published
2003-11
Volume
4
Issue
6
Pages
457-465
ISSN
  • 1527-2737
  • 1534-6285
DOI
10.1007/s11934-003-0027-x
Cited by
68
References
3
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.